[4] When carnitine cannot be transported into tissues, fatty acid oxidation is impaired, leading to a variety of symptoms such as chronic muscle weakness, cardiomyopathy, hypoglycemia and liver dysfunction
Novo, the lawsuit claims, was aware of the need to warn patients and prescribing physicians of the risk of gastroparesis but failed to do so
So its not surprising that a meaningful portion of patients starting Ozempic or compounded semaglutide are already managing ADHD, often with stimulant medications like Adderall or Vyvanse
Patients were followed up until the first outcome occurrence, the last encounter before study end (November 5, 2024), or 2 years from the index event
Why weight loss is not the end of the treatment pathway During active GLP-1 treatment, many people experience reduced appetite, fewer food thoughts, and greater control over eating
Here's the complete regulatory history: FDA Approval Timeline Date Event Details November 10, 2010 Original FDA Approval Egrifta approved for HIV-associated lipodystrophy (reduction of excess abdominal fat in HIV-infected patients with lipodystrophy) September 2019 Egrifta SV Approval Date Single-vial reformulation approved (simplified reconstitution vs
